Raphaela Goldbach-Mansky

Dr. Raphaela Goldbach-Mansky serves as Research Professor and Principal Investigator at the National Institutes of Health (NIH), where she leads the Translational Autoinflammatory Disease Section at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Her work bridges clinical rheumatology with cutting-edge molecular research to address rare autoinflammatory disorders.

Her academic foundation includes:

• Medical degree from University Witten-Herdecke, Germany
• Combined residency in Internal Medicine and Pediatrics at Case Western Reserve University
• Rheumatology fellowship at NIAMS/NIH

Goldbach-Mansky's research centers on interferonopathies and monogenic autoinflammatory diseases, with emphasis on CANDLE, SAVI, and COPA syndromes. She pioneers cytokine-targeted therapies and JAK inhibitor applications while developing diagnostic biomarkers through gene expression profiling. Her translational approach integrates patient phenotyping with molecular mechanisms to establish treatment protocols for these life-threatening conditions.

Recent publications reveal accelerating focus on personalized management strategies for autoinflammatory disorders, particularly through stem cell modeling of genetic mutations and refinement of flare criteria for JAK inhibitor therapy. Her work increasingly addresses interferon signaling pathways across multiple disease entities, demonstrating cross-diagnostic therapeutic principles for type I interferon-mediated conditions.

As Specialty Chief Editor for Frontiers in Immunology (Autoinflammatory and Autoimmune Disorders sections), she shapes scholarly discourse in the field despite no specific awards being documented in available materials.

Her NIH program directs substantial research funding for clinical trials and mechanistic studies, mentoring a multidisciplinary team of clinicians and scientists. While specific trainee names aren't listed, her principal investigator role implies supervision of postdoctoral fellows and clinical researchers in rare disease investigation.

The Translational Autoinflammatory Disease Section operates as a global referral center, combining patient care with laboratory discovery. Current initiatives include developing iPSC models for genetic validation, establishing international registries, and testing novel STING pathway inhibitors to address unmet therapeutic needs in interferonopathies.